This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Paroxysmal nocturnal haemoglobinuria [Marchiafava-Micheli]발작성 야간헤모글로빈뇨

ICD-10: D59.5 | Synonyms: PNH, Marchiafava-Micheli syndrome, Paroxysmal nocturnal hemoglobinuria, GPI-deficient blood cell disorder

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Initial description: Marchiafava and Micheli

Paroxysmal nocturnal hemoglobinuria (PNH) was first described in 1882 by William Gull in a patient with hematuria and anemia, and in 1928 the Italian physicians Ettore Marchiafava and Alessio Micheli systematically described the clinical features of this syndrome. It is also called 'Marchiafava-Micheli syndrome' after them. Initially, paroxysmal nocturnal hemoglobinuria was recognized as the characteristic symptom, but it was later found that nocturnal hemoglobinuria actually appears in only about 25% of all patients.

Discovery of complement susceptibility

In 1937, Ham and Dingle discovered that PNH red blood cells are selectively lysed in acidified serum and developed the 'Ham test (acid hemolysis test)'. Subsequently, in the 1960s–1970s, Rosse et al. established that PNH red blood cells are abnormally susceptible to complement activation and proposed that this is related to a deficiency of GPI (glycosylphosphatidylinositol)-anchored proteins.

Discovery of the PIG-A gene

In 1993, Miyata et al. and Takeda et al. identified PIGA, the causative gene of PNH. The PIGA gene encodes the enzyme that catalyzes the first step of GPI anchor biosynthesis and is located on the X chromosome. It was revealed that somatic PIGA variants cause a deficiency of GPI-anchored proteins (CD55, CD59, etc.), resulting in complement susceptibility.

Eculizumab's revolution in PNH treatment

In 2007, eculizumab (a terminal complement C5 inhibitor) was first approved by the FDA as a treatment for PNH, shifting the paradigm of PNH treatment. The introduction of eculizumab achieved suppression of hemolysis, prevention of thrombosis, and improved survival.

2. Causes

Somatic variants of the PIGA gene

The cause of PNH is an acquired (somatic) variant of the PIGA gene in hematopoietic stem cells. Because the PIGA gene is located on the X chromosome, in males (XY) a variant in a single PIGA allele alone completely blocks GPI synthesis. In females (XX), a single PIGA variant can also be clinically expressed due to X inactivation (lyonization).

GPI-anchored protein deficiency

When GPI anchor biosynthesis is halted by PIGA variants, all of the more than 50 cell surface proteins that depend on the GPI anchor become deficient. The most important in PNH pathology is the deficiency of the complement regulatory proteins CD55 (DAF, decay-accelerating factor) and CD59 (MAC-inhibitory protein). CD55 inhibits the formation of C3/C5 convertases, and CD59 inhibits the formation of the MAC (membrane attack complex).

Expansion of the PNH clone and immune escape

The reason PNH hematopoietic stem cell clones have a proliferative advantage over normal hematopoietic stem cells is explained by immune escape. It is understood that, under the autoimmune T-cell attack associated with aplastic anemia, GPI-deficient clones have a relative survival advantage and expand selectively.

3. Genetics

Somatic variants (acquired disease)

PNH is a clonal hematologic disease caused by acquired somatic variants. Because it is not a germline variant, it is not inherited. PIGA variants arise in hematopoietic stem cells, and GPI deficiency appears in all blood cells (red blood cells, white blood cells, platelets) derived from that clone.

PNH clone size and clinical phenotype

PNH clone sizeClinical significanceThrombosis risk
1~10%Small clone, asymptomatic or mild symptomsLow
10~50%Moderate symptoms (hemolysis, anemia)Moderate
50% or moreSevere PNH, hemoglobinuriaMarkedly increased

Association between PNH and aplastic anemia

PNH and aplastic anemia (AA) are closely associated. Small PNH clones are found in 30–50% of AA patients, and conversely, some PNH patients progress to aplastic anemia. These two diseases are understood as conditions on a continuum that share autoimmune-mediated suppression of hematopoiesis and immune escape of the PNH clone.

4. General epidemiology

Worldwide prevalence

PNH is a rare disease with an estimated incidence of 1–2 per million population per year. It is estimated that there are about 10,000–20,000 patients worldwide. The incidence in Western countries is about 1 per million, but relatively higher incidence is reported in East Asia (Korea, Japan, China, Thailand) due to the association with aplastic anemia.

Status in Korea

In Korea, PNH is managed as a rare hematologic disease. According to domestic studies, the frequency of PNH clones is high in patients with aplastic anemia, a phenomenon commonly observed in East Asian populations. Registration and management of patients treated with eculizumab are carried out mainly at specialized hematology centers in Korea, and it is eligible for the rare disease Special Copayment Reduction.

Age and sex distribution

PNH occurs mainly in young adults (median age of onset 35–40 years), but also occurs in children and the elderly. There is no clear sex difference, but pregnancy-related exacerbation of PNH occurs characteristically in women.

5. Pathophysiology

Complement-mediated intravascular hemolysis

Because of CD59 and CD55 deficiency, PNH red blood cells are susceptible to the MAC formed by continuous low-level activation (tick-over) of the alternative complement pathway. In particular, the origin of the name 'paroxysmal nocturnal' is that mild acidosis caused by reduced respiration during sleep promotes complement activation, increasing intravascular hemolysis at night. In reality, continuous intravascular hemolysis is ongoing and is not limited to nighttime.

Mechanism of thrombosis

In PNH, thrombosis is one of the main causes of death. The mechanism of thrombosis is multifactorial. ① Due to GPI deficiency in platelets, CD59 is absent, so platelets are activated by complement, increasing aggregation. ② Free hemoglobin from intravascular hemolysis consumes NO (nitric oxide), reducing vasodilation and increasing platelet activation. ③ Increased tissue factor expression activates coagulation. Thrombi occur in both veins (hepatic veins, portal vein, cerebral venous sinuses, mesenteric veins) and arteries.

NO depletion and clinical symptoms

Free hemoglobin released by intravascular hemolysis rapidly consumes plasma NO, and released arginase degrades L-arginine, the NO precursor. NO depletion causes symptoms such as smooth muscle spasm, esophageal spasm, abdominal pain, erectile dysfunction, renal vasoconstriction, and hypertension.

6. Symptoms

Hemolysis-related symptoms

Fatigue, pallor, and dyspnea appear as symptoms of chronic anemia. Hemoglobinuria: the typical symptom is red to brown urine as hemoglobin is excreted in the urine due to intravascular hemolysis (in reality, only about 25% of patients experience it). Jaundice (elevated indirect bilirubin). Abdominal pain, back pain, dysphagia (esophageal spasm), and erectile dysfunction occur due to smooth muscle spasm from NO depletion.

Thrombosis

Thrombosis is the most serious complication and a main cause of death in PNH. Hepatic vein thrombosis (Budd-Chiari syndrome, about 40%), portal vein thrombosis, cerebral venous sinus thrombosis, and mesenteric vein thrombosis are characteristic. Arterial thrombosis (stroke, myocardial infarction) also occurs. Thrombotic events can also present acutely and are life-threatening.

Bone marrow failure symptoms

When PNH is accompanied by aplastic anemia, pancytopenia appears. Recurrent infections due to leukopenia and bleeding due to thrombocytopenia are the main symptoms.

7. Signs

Physical examination findings

Pallor, jaundice, and hemoglobinuria (change in urine color) are the main physical signs. Splenomegaly is rare. When Budd-Chiari syndrome develops, abdominal distension, ascites, hepatomegaly, and abdominal tenderness are observed. When cerebral venous sinus thrombosis develops, headache, signs of increased intracranial pressure, and altered consciousness appear.

Laboratory findings

Complete blood count: depending on severity, normal to severe anemia (Hb 5–11 g/dL), thrombocytopenia, leukopenia (with accompanying AA). Blood smear: normocytic normochromic anemia, increased reticulocytes (hemolytic response). Biochemistry: markedly elevated LDH (a sensitive marker of intravascular hemolysis), decreased or absent haptoglobin, elevated indirect bilirubin, decreased serum iron. Urinalysis: hemoglobinuria, hemosiderinuria.

Flow cytometry findings

Classification of GPI-deficient blood cells on peripheral blood flow cytometry: PNH type III (complete GPI deficiency), type II (partial GPI deficiency), type I (normal). The FLAER (fluorescent aerolysin) assay is the standard method for quantifying PNH clones in white blood cells. The proportion of CD59-deficient red blood cells correlates with clinical severity.

8. Screening

Situations suggesting PNH

PNH screening is performed in the following clinical situations: ① unexplained hemolytic anemia, ② unexplained thrombocytopenia, ③ unexplained thrombosis (especially at unusual sites), ④ aplastic anemia, ⑤ refractory anemia (MDS), ⑥ anemia accompanied by abdominal pain/erectile dysfunction/dysphagia, ⑦ patients with hemoglobinuria.

Screening using flow cytometry

Peripheral blood flow cytometry is the standard method for PNH screening. GPI-deficient cells are quantified using CD55, CD59 (red blood cells), FLAER, CD14, CD16 (white blood cell lineages). High-sensitivity analysis capable of detecting a clone size of 0.01% or more is recommended.

The former Ham test (acid hemolysis test)

The Ham test was formerly the standard for PNH diagnosis, but it has now been replaced by flow cytometry, which is more sensitive and accurate. However, it is still used in some resource-limited settings.

9. Diagnosis

Flow Cytometry: the standard diagnostic method

High-sensitivity flow cytometry is the standard for PNH diagnosis and quantification of clone size. GPI-deficient cells in white blood cells (neutrophils, monocytes) are quantified using FLAER/LAIP (fluorescent aerolysin, lineage-associated immunophenotyping). CD59-deficient red blood cells are also quantified. A PNH clone size of 1% or more (intermediate or greater) is considered clinically significant.

Bone marrow examination

When accompanying aplastic anemia is suspected, bone marrow aspiration and biopsy are performed. Bone marrow cellularity, cell morphology, and chromosomal analysis are essential to determine whether AA and MDS are present.

Differential diagnosis

Hemolytic anemia: autoimmune hemolytic anemia (positive direct Coombs test), hereditary spherocytosis, G6PD deficiency, etc. Thrombotic microangiopathy (TMA): TTP (decreased ADAMTS13), aHUS (complement variants). Aplastic anemia: bone marrow failure with accompanying PNH clone. Myelodysplastic syndrome (MDS): abnormal blood cell morphology, chromosomal abnormalities.

10. Treatment

Eculizumab

Eculizumab is a C5-inhibiting monoclonal antibody approved by the FDA as a treatment for PNH in 2007. Eculizumab markedly reduces intravascular hemolysis, lowers thrombosis risk, reduces transfusion dependence, and improves quality of life. Administration: an initial induction dose (600 mg, weekly for 4 weeks) followed by a maintenance dose (900 mg, every 2 weeks). Meningococcal vaccination is mandatory before starting treatment.

Ravulizumab

A long-acting C5 inhibitor whose half-life is 4 times longer than that of eculizumab, allowing administration every 8 weeks. It shows efficacy equivalent to eculizumab while reducing dosing frequency, increasing patient convenience. FDA approved in 2019.

New agents

Proximal complement inhibitors such as pegcetacoplan (a C3 inhibitor, FDA approved in 2021) and danicopan (an oral factor D inhibitor) have been developed as new treatment options that additionally suppress the extravascular hemolysis that persists during eculizumab treatment.

Supportive care and hematopoietic stem cell transplantation

Transfusion (packed red blood cells): supportive care for severe anemia. Folic acid supplementation: replaces folate depleted by chronic hemolysis. Anticoagulation therapy: long-term anticoagulation when thrombosis occurs or in high-risk patients. Allogeneic hematopoietic stem cell transplantation is the only cure for PNH, but since the advent of eculizumab it is performed only in selected patients (severe PNH + aplastic anemia, HLA-matched sibling donor).

11. Prognosis

Prognosis before eculizumab

Before eculizumab, the median survival of PNH was poor, at about 10–15 years after diagnosis. The main causes of death were thrombosis (35–40%), bone marrow failure (infection, bleeding, about 30%), and transformation (MDS or acute leukemia, 5–10%). The 5-year survival rate was only about 60–70%.

Prognosis after eculizumab

The survival rate of PNH patients treated with eculizumab has improved to a level almost equivalent to that of the general population. Intravascular hemolysis is suppressed by 95% or more, thrombotic events are markedly reduced, and transfusion dependence is greatly reduced. However, because eculizumab does not eliminate the PNH clone itself, long-term treatment is required.

Natural course

In some PNH patients (about 15–20%), spontaneous remission, in which the PNH clone spontaneously disappears or decreases, has been reported. Transformation to MDS or acute myeloid leukemia occurs in less than 1%.

12. Prevention

Thrombosis prevention

In PNH, prevention of thrombosis is key to improving prognosis. In patients with a clone size of 50% or more or at high risk, combining anticoagulation therapy (warfarin, low-molecular-weight heparin) with eculizumab treatment is recommended. Because eculizumab treatment itself markedly lowers thrombosis risk, the need for anticoagulation in patients receiving eculizumab is determined individually.

Prevention of meningococcal infection

In patients treated with eculizumab/ravulizumab, the risk of infection with encapsulated bacteria, including meningococcus, is greatly increased. Vaccination with the quadrivalent meningococcal vaccine (MenACWY) and the meningococcal B vaccine before starting treatment is mandatory. Revaccination every 3–5 years during treatment is recommended.

Management during pregnancy

In PNH patients, pregnancy markedly increases thrombosis risk. Adequate counseling and an eculizumab treatment plan are needed before planning pregnancy. Data on the safety of eculizumab use during pregnancy are accumulating, and many centers currently recommend continuing eculizumab treatment during pregnancy.

Regular follow-up

In PNH patients, regular flow cytometry (monitoring of clone size), LDH, blood counts, and monitoring for thrombotic symptoms are needed. Treatment intensity is adjusted according to changes in clone size and clinical symptoms.

13. References

  1. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(12):3699-3709.
  2. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804-2811.
  3. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233-1243.
  4. Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993;259(5099):1318-1320.
  5. Bessler M, Mason PJ, Hillmen P, et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J. 1994;13(1):110-117.
  6. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840-1847.
  7. Risitano AM, Marotta S. Therapeutic complement inhibition in complement-mediated hemolytic anemias. Semin Hematol. 2018;55(3):167-177.
  8. Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH. Blood. 2019;133(6):540-549.
  9. Notaro R, Luzzatto L. Paroxysmal nocturnal hemoglobinuria: an acquired X-linked disorder. J Clin Invest. 1996;97(10):2308-2310.
  10. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin. JAMA. 2005;293(13):1653-1662.
  11. Lee JW, Jang JH, Kim JS, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol. 2013;97(6):749-757.
  12. Devalet B, Mullier F, Chatelain B, Dogne JM, Chatelain C. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria. Eur J Haematol. 2015;95(3):190-198.